aibioENDRA regains Nasdaq stockholders' equity compliance
Tickers NDRA
Nasdaq told ENDRA on July 8, 2026 that it regained compliance with the $2,500,000 minimum stockholders' equity requirement, but the company will be under a one-year panel monitor.
Key facts
- Company
- ENDRA Life Sciences Inc. (NASDAQ: NDRA)
- News type
- Listings
- Primary source
- ENDRA Life Sciences Inc. 8-K (2026-07-09)
ENDRA Life Sciences Inc. (Nasdaq: NDRA) received written notice from The Nasdaq Stock Market LLC on July 8, 2026, that it has regained compliance with Nasdaq's minimum stockholders' equity requirement. The company disclosed the notice in a Form 8-K dated July 8, 2026, and filed July 9, 2026, under Item 8.01 (Other Events). The filing is signed by Alexander Tokman, Chief Executive Officer. The regained compliance does not end the listing review. The company will be subject to a Discretionary Panel Monitor for one year from July 1, 2026, and the filing lays out what follows if the company falls out of compliance again during that period.
How the deficiency arose
The company disclosed earlier that on April 20, 2026, the Nasdaq Listing Qualifications Staff sent a letter saying that ENDRA's stockholders' equity, as reported in its Annual Report on Form 10-K for the year ended December 31, 2025, was below the $2,500,000 minimum required for continued listing under Nasdaq Listing Rule 5550(b)(1). On April 27, 2026, the company requested a hearing before the Nasdaq Hearing Panel, as the letter allowed. The hearing was held on May 28, 2026.
The July 8, 2026 notice closed that matter. The filing says the company is now in compliance with the Minimum Stockholders' Equity Requirement, under the terms of the Nasdaq notice.
What the monitor means
The company will be subject to a Discretionary Panel Monitor under Nasdaq Listing Rule 5815(d)(4)(A) for a period of one year from July 1, 2026. The filing spells out what happens if the Staff finds the company out of compliance with any of Nasdaq's Listing Rules during that period.
In that case, the company will not be permitted to give the Staff a plan of compliance for that deficiency. The Staff will not be permitted to grant additional time to regain compliance, and the company will not get the applicable cure or compliance period under Rule 5810(c)(3). Instead, the Staff will issue a Delist Determination Letter. The company would then have an opportunity to request a new hearing with the initial Panel, or with a newly convened Hearings Panel if the initial Panel is unavailable, and to respond and present its case to that panel as provided by Listing Rule 5815(d)(4)(C).
The filing states plainly that the company's securities may be delisted from Nasdaq at that time. The company does not describe any other step it plans to take during the monitoring period.
Financial position
The company's XBRL data, from its annual report on Form 10-K for 2025 filed March 31, 2026, show research and development expense of $1.8 million for 2025, compared with $3.2 million for 2024. The net loss was $7.0 million for 2025, compared with $11.5 million for 2024. Cash used in operations was $5.2 million in 2025, compared with $7.4 million in 2024.
The company's principal executive offices are at 3600 Green Court, Suite 350, in Ann Arbor, Michigan. Its common stock, with a par value of $0.0001 per share, trades on The Nasdaq Stock Market LLC under the symbol NDRA. The filing gives no stockholders' equity figure, so this story does not state one.
The risks ahead
ENDRA has regained compliance, but it has no margin for another listing problem. For one year from July 1, 2026, any new finding of non-compliance with Nasdaq's Listing Rules brings a Delist Determination Letter, with no plan of compliance and no extra time. The company says its securities may be delisted at that time. Its latest annual figures show a net loss of $7.0 million and cash used in operations of $5.2 million for 2025. The filing describes no other step the company plans to take during the monitoring period.